GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » Revenue

Daiichinkyo Co (Daiichinkyo Co) Revenue : $10,985 Mil (TTM As of Mar. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co Revenue?

Daiichinkyo Co's revenue for the three months ended in Mar. 2024 was $2,860 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was $10,985 Mil. Daiichinkyo Co's Revenue per Share for the three months ended in Mar. 2024 was $1.49. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $5.73.

During the past 12 months, the average Revenue per Share Growth Rate of Daiichinkyo Co was 25.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 19.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Daiichinkyo Co's highest 3-Year average Revenue per Share Growth Rate was 19.00% per year. The lowest was -3.60% per year. And the median was 1.70% per year.


Daiichinkyo Co Revenue Historical Data

The historical data trend for Daiichinkyo Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co Revenue Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9,118.77 8,854.87 8,811.90 9,564.84 10,690.85

Daiichinkyo Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,470.38 2,481.89 2,539.88 3,104.05 2,859.59

Competitive Comparison of Daiichinkyo Co's Revenue

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Revenue distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's Revenue falls into.



Daiichinkyo Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $10,985 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSKYF) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Daiichinkyo Co Revenue Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co (Daiichinkyo Co) Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2021, approximately half of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first U.S approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.